Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2019 | 1 |
2020 | 1 |
2021 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours.
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):907-921. doi: 10.1007/s00259-019-04499-x. Epub 2019 Sep 6.
Eur J Nucl Med Mol Imaging. 2020.
PMID: 31492995
Review.
Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of 177Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells.
Shah RG, Merlin MA, Adant S, Zine-Eddine F, Beauregard JM, Shah GM.
Shah RG, et al. Among authors: adant s.
Cancers (Basel). 2021 Jan 10;13(2):232. doi: 10.3390/cancers13020232.
Cancers (Basel). 2021.
PMID: 33435224
Free PMC article.
Item in Clipboard
Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor.
Purohit NK, Shah RG, Adant S, Hoepfner M, Shah GM, Beauregard JM.
Purohit NK, et al. Among authors: adant s.
Oncotarget. 2018 May 15;9(37):24693-24706. doi: 10.18632/oncotarget.25266. eCollection 2018 May 15.
Oncotarget. 2018.
PMID: 29872498
Free PMC article.
Item in Clipboard
Cite
Cite